首页 | 本学科首页   官方微博 | 高级检索  
     

醒脑静注射液联合吡拉西坦治疗脑挫裂伤的临床研究
引用本文:张锋,吴晓宇,许西海. 醒脑静注射液联合吡拉西坦治疗脑挫裂伤的临床研究[J]. 现代药物与临床, 2022, 37(6): 1248-1252
作者姓名:张锋  吴晓宇  许西海
作者单位:天津市宁河区医院 神经外科, 天津 301500;沧州市人民医院 神经外科, 河北 沧州 061001
基金项目:河北省医学科学研究课题计划项目(20200293)
摘    要:目的 探讨醒脑静注射液联合吡拉西坦注射液治疗脑挫裂伤的临床疗效。方法 选取2020年1月—2021年11月天津市宁河区医院收治的94例脑挫裂伤患者,根据随机数字表法将所有患者分为对照组和治疗组,每组各47例。对照组静脉滴注吡拉西坦注射液,40 mL加入250 mL生理盐水,1次/d。治疗组在对照组治疗的基础上静脉滴注醒脑静注射液,20m L加入250 mL葡萄糖注射液充分稀释,1次/d。两组患者连续治疗2周。观察两组的临床疗效,比较两组患者的清醒时间、住院时间、神经缺损程度和昏迷程度以及血清中白细胞介素-8(IL-8)、血管内皮生长因子(VEGF)、神经元特异性烯醇化酶(NSE)的水平。结果 治疗后,治疗组的总有效率(95.74%)高于对照组(82.98%),组间比较差异显著(P<0.05)。治疗后,治疗组的清醒时间、住院时间明显短于对照组(P<0.05)。治疗后,两组美国国立卫生研究院卒中量表(NIHSS)评分低于治疗前,格拉斯哥昏迷量表(GCS)评分高于治疗前(P<0.05);治疗后,治疗组的NIHSS评分低于对照组,GCS评分高于对照组(P<0.05)。治...

关 键 词:醒脑静注射液  吡拉西坦注射液  脑挫裂伤  美国国立卫生研究院卒中量表评分  格拉斯哥昏迷量表评分  白细胞介素-8  血管内皮生长因子  神经元特异性烯醇化酶
收稿时间:2022-02-05

Clinical study on Xingnaojing Injection combined with piracetam in treatment of brain contusion and laceration
ZHANG Feng,WU Xiao-yu,XU Xi-hai. Clinical study on Xingnaojing Injection combined with piracetam in treatment of brain contusion and laceration[J]. Drugs & Clinic, 2022, 37(6): 1248-1252
Authors:ZHANG Feng  WU Xiao-yu  XU Xi-hai
Affiliation:Department of Neurosurgery, Tianjin Ninghe Hospital, Tianjin 301500, China; Department of Neurosurgery, Cangzhou People''s Hospital, Cangzhou 061001, China
Abstract:Objective To investigate the clinical efficacy of Xingnaojing Injection combined with Piracetam Injection in treatment of brain contusion and laceration. Methods Patients (94 cases) with brain contusion and laceration in Tianjin Ninghe Hospital from January 2020 to November 2021 were randomly divided into control and treatment groups, and each group had 47 cases. Patients in the control group were po administered with Piracetam Injection, 40 mL added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Xingnaojing Injection on the basis of the control group, 20 mL added into glucose injection 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the awake time, the hospital stay, the degree of nerve defect, the degree of coma, the serum levels of IL-8, VEGF, and NSE in two group were compared. Results After treatment, the total effective rate of the treatment group (95.74%) was higher than that of the control group (82.98%), and there was significant reference between two groups (P < 0.05). After treatment, the awake time and hospital stay in the treatment group were significantly shorter than those in the control group (P < 0.05). After treatment, the NIHSS score of two groups was lower than that before treatment, but the GCS score of two groups was higher than that before treatment (P < 0.05). After treatment, the NIHSS score of the treatment group was lower than that of the control group, but the GCS score of the treatment group was higher than that of the control group (P < 0.05). After treatment, the serum levels of IL-8, VEGF, and NSE in two groups were lower than those before treatment (P < 0.05), and the serum levels of IL-8, VEGF, and NSE in the treatment group were lower than those in the control group (P< 0.05). Conclusion Xingnaojing Injection combined with Piracetam Injection has curative effect in treatment of brain contusion and laceration, can improve the degree of coma, and reduce neurological deficit, with good safety.
Keywords:Xingnaojing Injection  Piracetam Injection  brain contusion and laceration  NIHSS score  GCS score  IL-8  VEGF  NSE
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号